FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to oncology, namely to agents for cancer treatment. The combination contains N-(3-methoxy-6-methylpyrazine-2-yl)-2-(4 -[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulfonamide and taxane or its derivatives, namely paclitaxel, docetaxel. The pharmaceutical composition contains such combinations in combination with one or more pharmaceutically acceptable diluents. Application of the combination for preparing the drug and treating or preventing cancer.
EFFECT: use of the combinations, the pharmaceutical composition allows providing higher clinical effectiveness.
12 cl, 6 ex, 3 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION CONTAINING N-(3-METHOXY-5-METHYLPYRAZINE-2-YL)-2-(4-[1,3,4-OXADIAZOL-2-YL]PHENYL)PURIDINE-3-SULPHONAMIDE AND LHRH-ANALOGUE AND/OR BIPHOSPHONATE | 2004 |
|
RU2398588C2 |
| THERAPEUTIC APPLICATION | 2003 |
|
RU2340343C2 |
| METHODS AND COMPOSITIONS FOR TREATING CANCER | 2009 |
|
RU2508116C2 |
| COMBINED CHEMOTHERAPY | 2001 |
|
RU2284818C2 |
| COMBINED CHEMOTHERAPY | 2010 |
|
RU2587013C2 |
| COMBINED CHEMOTHERAPY | 2006 |
|
RU2429838C2 |
| COMBINATIONS INCLUDING EPOTHILONES, AND THEIR PHARMACEUTICAL APPLICATION | 2002 |
|
RU2375058C2 |
| TREATMENT OF PROLIFERATIVE DISEASES WITH EPOTHILONE DERIVATIVES AND RADIATION | 2004 |
|
RU2381799C2 |
| COMPOSITIONS CONTAINING SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 | 2002 |
|
RU2333754C2 |
| COMBINATION OF PHOSPHATIDYL INOSITOL-3-KINASE (PI3K) INHIBITOR AND mTOR INHIBITOR | 2009 |
|
RU2538683C2 |
